Enbrel Articles
57% of teen patients on Enbrel see PASI 75
21 January 2008
French drug sales rose 4%-4.5% in 2007
21 January 2008
Abraxis licenses Abraxane to Green Cross for Korea
3 December 2007
Stock Commentary - New York week to Nov 26, 2007
3 December 2007
Drug sales up 5% in year to September 2007
26 November 2007
"Devastating" AS ruling by the NICE condemned
19 November 2007
New head of Wyeth France to manage future growth
29 October 2007
Drug sales up 5% in year to August 2007
22 October 2007
Drug sales up 5% in year to July 2007
24 September 2007
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
Japan stock market week to May 7, 2007
14 May 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
Wyeth's 1st-qtr income up 12% to $1.25B
30 April 2007
Zeltia's Yondelis enters Phase III
9 April 2007
Wyeth's income up 17%, but shares fall 2.5%
5 February 2007
RA biological competitors spent $195M on promotion
8 January 2007
Wyeth updates on UK roll out of Enbrel PFS
18 December 2006
Amgen presents Ph IV data on Enbrel
20 November 2006
Wyeth's income climbs 33% to $1.16B in 3rd-qtr, on continued success of Enbrel and Prevnar
30 October 2006
Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
16 October 2006
Enbrel demonstrates long-term safety profile
16 October 2006
Enbrel launched in prefilled syringes UK
9 October 2006
Blockbuster status forecast for Enbrel by 2010
18 September 2006
Amgen's 2nd-qtr 2006 sales up 14% to $3.6B
31 July 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
Enbrel and MTX therapy shows promise in RA trial
3 July 2006
Wyeth's Enbrel cuts doctor visits in PA
12 June 2006
Wyeth's 1st-qtr 2006 revenues $4.8B, up 6%
1 May 2006
Amgen sees $1B profits in 1st-qtr 2006
24 April 2006
Wyeth increases stake in Wyeth KK
17 April 2006
Wyeth moves into profit but disapoints
6 February 2006
Wyeth opens Ireland biotech production unit
19 September 2005
FDA licenses to Amgen production facilities
12 September 2005
US FDA advisers urge appro of B-MS' Orencia
12 September 2005
Enbrel drives Wyeht's 2nd-qtr sales
1 August 2005
Stock Commentary - New York
18 July 2005
Japan stock market week to June 27
4 July 2005
FDA OKs additional indication for Enbrel
6 June 2005
Amgen posts 26% EPS hike, raises forecast
25 April 2005
Wyeth 1st-qtr earnings rocket 44%
25 April 2005
Wyeth to take full control of Takeda JV
11 April 2005
Japan stock market week to April 4
11 April 2005
Enbrel improves psoriasis symptoms, study confirms
28 February 2005
Abbot's Humira gives promising psoriasis results
28 February 2005
Japan stock market week to February 21
28 February 2005
Japan stock market week to January 31
7 February 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Enbrel approved for RA in Japan
31 January 2005
Preclinical program for RhuDex nearing completion
10 January 2005
New data for Amgen/Wyeth's Enbrel at ACR
25 October 2004
Enbrel cleared for psoriasis in EU
11 October 2004
Expanded US label for Amgen/Wyeth's Enbrel
4 October 2004
World dermatology mkt forecast to grow 8%/year through 2008
13 September 2004
Amgen's 2nd-qtr 2004 EPS jumps 27%
9 August 2004
CHMP recommends Enbrel for psoriasis
9 August 2004
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Scotland backs Enbrel in psoriatic arthritis
26 July 2004
UPDATE: Enbrel gets OK from FDA for psoriasis
10 May 2004
Enbrel gets OK from FDA for psoriasis
10 May 2004
Amgen's EPS for 1st-qtr 2004 jumps 36%
3 May 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Strong sales boost Amgen profit
2 February 2004
Charges pull Wyeth earnings down 79%
2 February 2004
Enbrel cleared for new use in EU
26 January 2004
Amgen forecasts 18%-30% rise in 2004 profits, boosted by lead drugs
22 December 2003
New dosing option for Enbrel OKed by FDA
27 October 2003
Wyth sees 3rd-quarter loss on charges
27 October 2003
Profits up at Amgen on strong sales growth
27 October 2003
NICE plans six new pharma guidelines for NHS in England/Wales
20 October 2003
Enbrel recommended in EU for new use
6 October 2003
Wyeth to boost sales 60% in Japan with new drug launches
22 September 2003
FDA clears expanded use of Enbrel
11 August 2003
Enbrel gets FDA OK for expanded use
4 August 2003
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
